A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.

NCT06654947 | Not Yet Recruiting Phase 2

• 1 other identifier: ST-BTC-001
• Study Type: interventional
• Target: 23
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a single-arm, open-label, prospective clinical study aimed at observing and evaluating the efficacy and safety of surufatinib combined with immunotherapy and chemotherapy in the treatment of unresectable or metastatic biliary tract cancer.

Conditions

Biliary Tract Cancer

Outcome Measures

Primary Outcomes (1)

• Progression free survival (PFS)

  Tumor assessment will be performed using radiography method every 6 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1

  from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year

Secondary Outcomes (4)

• Objective response rate (ORR)

  from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year

• Overall survival (OS）

  from randomization until death due to any cause, assessed up to 3 year

• Disease control rate (DCR）

  from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year

• Safety and tolerance evaluated by incidence, severity and outcomes of AEs

  from first dose to 30 days post the last dose

Study Arms (1)

Experimental: Experimental

EXPERIMENTAL

Drug: Surufatinib+Toripalimab+GEMOX

Interventions

Surufatinib+Toripalimab+GEMOX DRUG

Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；GEMOX：Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W，Oxaliplatin：100mg/m2,ivgtt，d1，Q3W）

Experimental: Experimental

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Have fully comprehended this study and voluntarily signed the Informed Consent Form;
• Age ≥ 18 years;
• Inoperable or metastatic biliary tract carcinoma confirmed by histopathology or cytology;
• Hepatic function classified as Child-Pugh Class A (scores 5-6) or Class B with favorable prognosis (score ≤7) (refer to Appendix 3);
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (refer to Appendix 1);
• Anticipated survival ≥ 12 weeks;
• At least one measurable lesion according to RECIST 1.1 criteria (refer to Appendix 2);
• Essentially normal function of major organs and bone marrow:
• Complete blood count: WBC ≥ 4.0 × 10\^9/L, neutrophils ≥ 1.5 × 10\^9/L, platelets ≥ 100 × 10\^9/L, hemoglobin ≥ 90 g/L;
• Prothrombin time expressed as International Normalized Ratio (INR) ≤1.5 × upper limit of normal (ULN), and activated partial thromboplastin time (APTT) ≤1.5 × ULN;
• Hepatic function tests: Total bilirubin ≤ 1.5 × ULN; without liver metastasis, ALT/AST/ALP ≤ 2.5 × ULN; with liver metastasis, ALT/AST/ALP ≤ 5 × ULN;
• Renal function tests: Serum creatinine ≤ 1.5 × ULN, and creatinine clearance (CCr) ≥ 60 mL/min (refer to Appendix 6);
• Cardiac function within normal limits, with left ventricular ejection fraction (LVEF) ≥ 50% as determined by two-dimensional echocardiography.
• Male or female patients of reproductive potential voluntarily agree to use effective contraception during the study and for six months following the final administration of study medication, such as dual-barrier methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female patients will be considered to have reproductive potential unless they have undergone spontaneous menopause, surgically-induced menopause, or have had a hysterectomy, bilateral salpingectomy, or ovarian irradiation with radioisotopes.

You may not qualify if:

• Patients who relapsed within 6 months after previous immunosuppressive therapy;
• Clinically symptomatic central nervous system metastases and/or carcinomatous meningitis;
• Biliary obstruction that, in the investigator's judgment, has not resolved or requires anti-infective treatment within 14 days prior to the first study drug administration despite clinical intervention;
• History of liver transplantation;
• Active autoimmune disease or immunodeficiency;
• Any surgery or invasive treatment or procedure (excluding venous catheterization, puncture drainage, etc.) within 4 weeks prior to study enrollment;
• Uncontrolled hypertension not managed with medication, defined as: systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg;
• Urinalysis indicating proteinuria ≥2+ and, with a 24-hour urine protein quantification \>1.0g;
• Current presence of any disease or condition affecting drug absorption, or the patient's inability to orally ingest sorafenib;
• Current active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases, or active bleeding from an unresected tumor, or other conditions deemed likely to cause gastrointestinal bleeding or perforation by the investigator;
• Active bleeding or severe bleeding tendency;
• Significant clinical cardiovascular disease, including but not limited to acute myocardial infarction within 6 months prior to enrollment, severe/unstable angina, or coronary artery bypass grafting; New York Heart Association (NYHA) classification \> grade 2 for congestive heart failure; ventricular arrhythmias requiring drug therapy; electrocardiogram (ECG) showing QTc interval ≥480 milliseconds;
• Active or uncontrolled severe infection (≥Grade 2 infection by CTC AE);
• Known human immunodeficiency virus (HIV) infection; known clinically significant liver disease history, including viral hepatitis \[known carriers of hepatitis B virus (HBV) must exclude active HBV infection, i.e., HBV DNA positive (\>1×10\^4 copies/mL or \>2000 IU/mL); known hepatitis C virus (HCV) infection and HCV RNA positive (\>1×10\^3 copies/mL), or other types of hepatitis, cirrhosis\];
• Unresolved toxicities higher than Grade 1 by CTCAE from any previous anticancer treatment, excluding alopecia, lymphocytopenia, and ≤Grade 2 neurotoxicity caused by oxaliplatin (excluding well-controlled immune-related thyroiditis and pituitary inflammation with hormone replacement therapy);

Sponsors & Collaborators

• Fujian Cancer Hospital: lead

MeSH Terms

Conditions

Biliary Tract Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Biliary Tract Diseases; Digestive System Diseases

Central Study Contacts

Sha Hua

CONTACT

13763820570; huangsha0210@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 21, 2024
• First Posted: October 23, 2024
• Study Start: January 1, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2027
• Last Updated: December 16, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share